Hard Capsules, 10mg

Capsules 25mg, 50mg, 100mg
Liquid 100mg/1mL
Concentrate for intravenous infusion 50mg/1mL

Prescribe by brand name for transplant patients.

For use in other indications see sections 01.05.03, 10.01.03, and 11.11.

Solution for infusion. Each 20 mL vial contains 1 080 mg of pegcetacoplan.

Tablets 1mg, 5mg
e/c tablets 2.5mg

25mg tablets are classified as 
 
There is no evidence that e/c prednisolone reduces the risk of gastrointestinal side effects. Uncoated tablets should be prescribed first line together with a PPI if necessary.

Also see sections 10.01.02.02, 06.03.02, 01.05.02, 11.04.01.

Brand name prescribing essential

For prophylaxis of graft rejection

Dailiport modified release oral capsules are recommended for all patients who are newly prescribed modified release tacrolimus for transplant rejection – RAG status RED for new patients
Please note:
Dailiport modified release capsules are not bioequivalent to Adoport immediate release capsules and do not replace Adoport capsules.
Existing patients using Advagraf modified release capsules will remain on Advagraf and are not routinely switched to Dailiport. If a prescriber considers that switching a patient to a different brand of oral tacrolimus would be of benefit, the change requires careful supervision and therapeutic monitoring by an appropriate specialist.

See section 13.05.03 for use in dermatology.

Capsules 7.9mg